Mabwell’s Denosumab Biosimilar Shows Similar Efficacy To Xgeva
The Phase III Trial Enrolled Solid Tumor Patients With Bone Metastasis
Executive Summary
Mabwell’s denosumab biosimilar MW032, which awaits approval in China, achieved similar efficacy and safety profiles as the originator Xgeva in oncology patients.